Ftse Mib
33.881,50
0,74%
DAX
17.837,40
0,28%
S&P 500
5.011,12
-0,22%
NASDAQ Composite
15.601,50
-0,52%
Bitcoin
63.026,71
-0,76%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Assistente personale
Home Investire Azioni Europa EU Crossject (ALCJ) Crossject (ALCJ) Notizie

Crossject

ALCJ
2,04
-0,035 (-1,69%)
18 Apr 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: Euronext
Tipo: Azione Ordinaria
Valuta: EUR

Ultime notizie

Data Ora Fonte Titolo
10/4/202416:30GLOBECrossject : Information relative au nombre total de droits..
02/4/202418:35GLOBECrossject trading on Euronext to resume as usual on..
02/4/202410:30GLOBECrossject advances in its U.S. Strategy and reports..
08/3/202407:30GLOBECrossject gender equality score reaches 96/100 in 2024
27/2/202408:30GLOBECrossject obtient un financement jusqu’à 12 millions d’euros..
06/2/202417:30GLOBECrossject publie une mise à jour stratégique de ses..
01/2/202418:15GLOBECrossject organisera un webcast le 6 février à 17h30 pour..
16/1/202417:15GLOBECrossject : Information relative au nombre total de droits..
09/1/202416:21GLOBECrossject to present at Biotech Showcase on January 9 at..
04/1/202418:00GLOBECrossject engage Syneos Health pour le lancement commercial..
22/12/202307:30GLOBECrossject signs ZEPIZURE® commercialization agreement for..
20/12/202316:40GLOBECrossject : Information relative au nombre total de droits..
28/11/202307:30GLOBECrossject annonce l’initiation de la couverture de son titre..
14/11/202317:35GLOBECrossject : Information relative au nombre total de droits..
05/10/202308:45GLOBECrossject : Information relative au nombre total de droits..
26/9/202317:35GLOBECrossject reports financial results and business highlights..
11/9/202317:35GLOBECrossject : Information relative au nombre total de droits..
11/9/202307:30GLOBECrossject annonce une nouvelle nette amélioration de sa..
05/9/202313:00GLOBECrossject reports successful completion of European and U.S...
05/9/202307:30GLOBECrossject reports successful completion of European and U.S...
08/8/202317:49GLOBECrossject : Information relative au nombre total de droits..
24/7/202318:00GLOBECrossject : Information relative au nombre total de droits..
20/7/202316:55GLOBECrossject signs new licensing agreement on ZENEO® Midazolam..
20/7/202307:30GLOBECrossject signe un nouvel accord de licence pour le..
10/7/202318:00GLOBECROSSJECT - Information relative au nombre total de droits..
30/6/202308:30GLOBECrossject répond aux questions posées par les actionnaires..
12/6/202318:00GLOBECrossject à l'écoute de ses actionnaires individuels et des..
05/6/202318:00GLOBECROSSJECT - Information relative au nombre total de droits..
01/6/202318:30GLOBECrossject - Appointment of Daniel Teper to the Crossject..
10/5/202318:00GLOBECrossject : Information relative au nombre total de droits..
28/4/202318:27GLOBECrossject - Mise à disposition du rapport financier annuel..
28/4/202318:16GLOBECrossject - Rapport financier annuel 2022
Apertura: 2,07 Min: 1,974 Max: 2,07
Chiusura: 2,075

La tua Cronologia

EU
ALCJ
Crossject
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network